Any current/future new fundraising through debt or equity?

The transcript provided from the earnings call does not mention any specific current or future plans for fundraising through debt or equity. The company highlights having significant cash and cash equivalents on hand and generating healthy free cash flows in excess of INR 1,000 crore per year after routine items. It mentions confidence in funding portfolio expansion (INR 6,000 crore over 3-4 years) primarily through existing funds and internal accruals, without indicating the need for additional fundraising. No direct references to new debt issuance or equity raising initiatives were found on

Any current/future capex/capital investment/strategic investment?

Apollo Hospitals is committed to spending over INR 8,000 crore for adding 4,300 beds over the next 3 to 4 years. INR 1,000 crore has already been spent on land acquisition and project development; the balance INR 6,000 crore will be spent over the next 3 to 4 years. Key projects include operationalizing facilities in Gurgaon, Pune, Kolkata, Hyderabad, and significant expansion in Bangalore's Sarjapur area with 700 additional beds via acquisition and greenfield development. Expansion also planned in Jubilee Hills, Secunderabad, and Gachibowli Hyderabad, boosting overall bed strength to 1,500 in

Future growth expectations in sales/revenue/volumes?

Pharmacy front-end business expected to grow over 20% in FY '26 and beyond. Digital business (Apollo 24/7) targeting 25%-30% GMV growth annually; aiming for INR 1,000 crore GMV to breakeven. Apollo HealthCo revenues grew 17% YoY in Q4, supported by omnichannel pharmacy and double-digit GMV growth; aiming to hit around INR 24,000 to 25,000 crore by FY '27. Diagnostics business targeting 2%-3% margin improvement this year; aiming for 20% EBITDA margin in next 2-3 years with volume growth through lab expansions. Apollo Pharmacy aims to increase market share from current 8% to 20% in 5-6 y

Future growth expectations in earnings/operating earnings/profits/EPS?

Diagnostics business aims for a high-teens volume growth starting this quarter, with a target EBITDA margin of 20% in about 2 years, improving 2-3% this year (Page 14). Apollo HealthCo expects to reach 7%+ EBITDA margin by FY '27 after rationalizing ESOP costs and achieving breakeven in digital losses; 24/7 operating expenses to reduce by 15-20% to INR 400-425 crore, aiding breakeven by Q3/Q4 FY '26 (Pages 12-13). Digital platform 24/7 plans 25-30% annual GMV growth, with breakeven expected near INR 1,000 crore GMV (Page 8). Overall consolidated EBITDA grew 26% YoY in FY '25, with Healthcare S

Apollo Hospitals Enterprise LtdQ1 FY26Healthcare Services

Apollo Hospitals Enterprise Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹8,922P/E: 68.5Market Cap: ₹1.3L CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Pharmacy front-end business expected to grow over 20% in FY '26 and beyond.
→Digital business (Apollo 24/7) targeting 25%-30% GMV growth annually; aiming for INR 1,000 crore GMV to breakeven.
→Apollo HealthCo revenues grew 17% YoY in Q4, supported by omnichannel pharmacy and double-digit GMV growth; aiming to hit around INR 24,000 to 25,000 crore by FY '27.
→Diagnostics business targeting 2%-3% margin improvement this year; aiming for 20% EBITDA margin in next 2-3 years with volume growth through lab expansions.
→Apollo Pharmacy aims to increase market share from current 8% to 20% in 5-6 years by adding 600 stores annually and expanding to new geographies.
→Specialty clinics and primary care clinics expected to grow in high teens.
→Digital insurance business started contributing; expected to grow significantly next year.
→New hospitals and bed additions planned, with operational expansion in Q3/Q4 FY '26 enhancing volumes and revenues.

Margin guidance

Category 1

→Diagnostics business aims for a high-teens volume growth starting this quarter, with a target EBITDA margin of 20% in about 2 years, improving 2-3% this year (Page 14).
→Apollo HealthCo expects to reach 7%+ EBITDA margin by FY '27 after rationalizing ESOP costs and achieving breakeven in digital losses; 24/7 operating expenses to reduce by 15-20% to INR 400-425 crore, aiding breakeven by Q3/Q4 FY '26 (Pages 12-13).
→Digital platform 24/7 plans 25-30% annual GMV growth, with breakeven expected near INR 1,000 crore GMV (Page 8).
→Overall consolidated EBITDA grew 26% YoY in FY '25, with Healthcare Services margins steady at ~24% despite new hospital additions; new bed additions expected to impact margins by ~140bps, offset by cost and revenue improvements (Pages 3, 5, 7).
→Pharmacy business targeted to achieve ~24% annual CAGR, reaching INR 24,000-25,000 crore revenue by FY '27, driven by front-end and digital growth (Page 10).
→Earnings growth supported by expansion in diagnostics, primary care clinics, and optimization in payer mix and case complexity (Pages 14, 2).

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript provided from the earnings call does not mention any specific current or future plans for fundraising through debt or equity.
→The company highlights having significant cash and cash equivalents on hand and generating healthy free cash flows in excess of INR 1,000 crore per year after routine items.
→It mentions confidence in funding portfolio expansion (INR 6,000 crore over 3-4 years) primarily through existing funds and internal accruals, without indicating the need for additional fundraising.
→No direct references to new debt issuance or equity raising initiatives were found on the discussed pages.

Order book

The transcript provided does not explicitly mention details about current or expected orderbook or pending orders for Apollo Hospitals Enterprise Ltd (AHEL). The discussion focuses primarily on business segments such as pharmacy expansion, digital business growth, diagnostics, healthcare services, mergers like Keimed, and capital expenditure timelines. Key related points are: - Apollo Pharmacy adding 375 to 500 outlets, expanding footprint, especially in western and northern India. - Keimed merger expected to complete in 15 months. - Gurgaon and Worli projects pending approvals and expected commissioning by end of Q4 FY25. - 24/7 digital business targeting cash breakeven by Q3/Q4 FY26 with GMV growth. - Distribution and Retail businesses are geographically distinct with no expected overlap. No direct reference to orderbook or pending orders figures is available on these pages.

Capex plans

Yes

→Apollo Hospitals is committed to spending over INR 8,000 crore for adding 4,300 beds over the next 3 to 4 years.
→INR 1,000 crore has already been spent on land acquisition and project development; the balance INR 6,000 crore will be spent over the next 3 to 4 years.
→Key projects include operationalizing facilities in Gurgaon, Pune, Kolkata, Hyderabad, and significant expansion in Bangalore's Sarjapur area with 700 additional beds via acquisition and greenfield development.
→Expansion also planned in Jubilee Hills, Secunderabad, and Gachibowli Hyderabad, boosting overall bed strength to 1,500 in Hyderabad and Bangalore.
→Apollo HealthCo is advancing the Keimed merger with 15 months timeline for completion.
→New insurance partnerships for Apollo 24/7 are expected to drive revenue, with no losses anticipated this fiscal year but significant margin increases expected next year.
→No intention to tie up with quick commerce platforms; focus remains on building in-house digital capabilities.

How does Apollo Hospitals Enterprise Ltd rank vs peers in Healthcare Services?

Pro feature

1Apollo Hospitals Enterprise Ltd

Rev 2Mar 1

See full Healthcare Services sector rankings

Want more stocks like Apollo Hospitals Enterprise Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio